Sernova Corp T.SVA

Sigil-gone

[BioTeck]

JUL 9, 2021 10:47 AM EDT

Sigilon Shares Dive After FDA Places Drug Study on Hold

The FDA notifies Sigilon that its Phase 1/2 study of SIG-001 for hemophilia A has been placed on clinical hold.

Sigilon Therapeutics (SGTX) plunged Friday after the Food and Drug Administration notified the biotech company that its Phase 1/2 study of SIG-001 for hemophilia A has been placed on clinical hold.

“The clinical hold was initiated following the company’s submission of a serious adverse event and temporary enrollment halt to the FDA,” Sigilon said in a statement.

The stock recently traded at $6.56, down 29%, putting it 82% lower for the past six months.

“To date, three patients have been dosed with SIG-001. The third patient, who received the highest dose of study drug, developed inhibitors to Factor VIII - a well-known complication of FVIII therapy,” Sigilon said.

“The patient is responding well to medical treatment, and his condition continues to improve,” the company added.

The company said the FDA has "requested additional information or data on factors potentially contributing to the development of inhibitors in this patient."

That would include “family history and immune stimulation from a recent vaccination"

[MoneyMouth]

[Metalsguy1]

Sigilon's chart is horrific but it is a pretty clear picture of how inept SVA is at generating market interest by comparison I am not a fan of Sigilons tech but the reality is that their 1 year high was the equivalent of $6+ for SVA. Nevermind the fact that they have a much tighter share structure.

[Mudlogger1]

Yes indeed. Siligon will require that "tighter share structure" for egress through their looming toilet bowl portal. Only one of the 9 Siligon directors holds shares and he dumped 200,000 at $10 on June 6th. Wonder why. That's hardly cause for calling SVA inept and then lauding Siligon's 1 year high as some great milestone when it has since vaporized. Great if you're just

[MustangSalley]

  Siligon has only the hemophilia trial that was halted. Siligon at least had a large market cap on its debut . Remember Siligon has Lilly supporting them with $100 million invesrment. Still does not excuse management for taking 15 % of flair as compensation. Oh Siligon has 31 million shares outstanding while Sva has 320 plus 45 million = 365 million shares outstanding .....we as

[MustangSalley]

Excuse my misspelling . 15% of float . Lilly has invested $100 million US into the diabetes program of Siligon not Hemophila for clarification . Sva on the other hand ,  management has taken 15% for themselves 45 million shares for future potential ? How on Earth are they going to get share price up to qualify for Nasdaq where true liquidity exists for investors . If Toleikis graduates to Tsx

[Mudlogger1]

"""'we as investors are here for a return on our investment , patient outcome is important but secondary Mudslinger."" Thanks for clarifying your stance Ms. Sally. Wow. In any event, return on investment will certainly follow patient outcome ...watch as Siligon circles the drain. 

[MustangSalley]

Timing is everything . Those who are first receive value. The fairness of value is a perception of the vendor and buyer. First to market is important , if you can build value longterm with licensing that is also fair . But with Sva trying to cure TD1 will require 100's of millions of dollars.  Semma was bought out by Vertex for almost $1 Billion dollars for unproven cells that were not

[Metalsguy1]

Hey Mud for brains. I could care less about Sigilons tech, etc. As a company Shill you have most expertly pivoted away from my main point, which I will reiterate so you might be able to get it through your thick skull. As behind as Sigilon is, their 52 week high is almost 6 times that of SVA. SvAs 52 week high could not even be sustained for 2 days.